Oishi K, Sonoda F, Iwagaki A, Kobayashi S, Nagatake T, Matsumoto K
Department of Internal Medicine, Nagasaki University, Japan.
Antimicrob Agents Chemother. 1992 Jul;36(7):1352-7. doi: 10.1128/AAC.36.7.1352.
The effects of the combination of a murine monoclonal antibody (MAb) specific for the O side chain of Pseudomonas aeruginosa Fisher immunotype 1 lipopolysaccharide and sparfloxacin in a neutropenic mouse model of P. aeruginosa pneumonia were examined. Under the condition that neither MAb at a dose of 500 micrograms per mouse administered intravenously nor a suboptimal dose of oral sparfloxacin (5 mg/kg of body weight) protected mice from challenge with a fatal dose, the combination therapy with MAb and sparfloxacin caused a significant increase in the survival rate (P less than 0.001 compared with either treatment alone). The effect of the combination was closely correlated to bacterial killing in plasma and lung tissue of infected mice. In vitro, a significant MAb-dependent, complement-mediated killing of P. aeruginosa was documented in the presence of sparfloxacin at one-half the MIC, while the killing was not observed in the absence of sparfloxacin. These in vivo and in vitro data suggest the usefulness of combination therapy with a lipopolysaccharide-reactive immunoglobulin G MAb and sparfloxacin in neutropenic patients with P. aeruginosa pneumonia.
研究了一种针对铜绿假单胞菌费舍尔免疫型1脂多糖O侧链的鼠单克隆抗体（MAb）与司帕沙星联合用药在铜绿假单胞菌肺炎中性粒细胞减少小鼠模型中的效果。在静脉注射剂量为每只小鼠500微克的单克隆抗体或口服次优剂量司帕沙星（5毫克/千克体重）均不能保护小鼠免受致死剂量攻击的情况下，单克隆抗体与司帕沙星联合治疗使存活率显著提高（与单独使用任一治疗方法相比，P<0.001）。联合用药的效果与感染小鼠血浆和肺组织中的细菌杀灭密切相关。在体外，在司帕沙星浓度为最低抑菌浓度一半的情况下，记录到单克隆抗体依赖的、补体介导的铜绿假单胞菌杀伤作用，而在没有司帕沙星的情况下未观察到这种杀伤作用。这些体内和体外数据表明，脂多糖反应性免疫球蛋白G单克隆抗体与司帕沙星联合治疗对铜绿假单胞菌肺炎中性粒细胞减少患者有用。
